Chardan Capital Reiterates Buy Rating for SAB Biotherapeutics with $20 Target

SAB Biotherapeutics received a reaffirmed "Buy" rating from Chardan Capital with a $20 target. The analyst maintains confidence in the company despite current market conditions. The average one-year target price is $9.25, with a high estimate of $12.00 and a low estimate of $7.00, indicating an upside of 371.94% from the current price of $1.96. The average brokerage recommendation is 1.8, indicating an "Outperform" status.